



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications
(949) 608-0841

XDx to Present at the Thomas Weisel 2009 Healthcare Conference

BRISBANE, CA, September 3, 2009 – XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests for the monitoring of immune-mediated conditions, today announced that Pierre Cassigneul, president and chief executive officer, is scheduled to present at the Thomas Weisel 2009 Healthcare Conference on Thursday, September 10, 2009 at 2:40 p.m. (EDT) at the Four Seasons Hotel in Boston.

About XDx

Based in Brisbane, California, XDx is a molecular diagnostics company focused on the discovery, development and commercialization of noninvasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed a proprietary new method for noninvasively monitoring immune system activity by measuring gene expression in a patient's peripheral blood. This work is the basis for AlloMap® Molecular Expression Testing, which provides transplant physicians with a new tool to aid in the identification of the probability of acute cellular rejection for post-cardiac transplant patient management.

Some of the AlloMap Molecular Expression Technology developed and implemented by XDx in heart transplant patient management may be applicable to other diseases that involve transplant rejection and the immune system. XDx's noninvasive technology offers the potential to decrease healthcare costs and significantly improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases.

XDx has several ongoing studies focused on AlloMap. The company anticipates results from its Invasive Monitoring Attenuation through Gene Expression (IMAGE) trial, a comparative efficacy clinical study designed to demonstrate the non-inferiority of clinical outcomes of heart transplant recipients managed with the AlloMap test compared to endomyocardial biopsy, at the end of 2009 or early 2010.